Menlo Park, CA, United States of America

Kenneth Albert Brameld

USPTO Granted Patents = 27 

 

 

Average Co-Inventor Count = 2.9

ph-index = 7

Forward Citations = 127(Granted Patents)


Location History:

  • Palo Alto, CA (US) (2012)
  • Hillsborough, CA (US) (2023)
  • Menlo Park, CA (US) (2015 - 2024)

Company Filing History:


Years Active: 2012-2025

Loading Chart...
Loading Chart...
Loading Chart...
27 patents (USPTO):

Title: Kenneth Albert Brameld: A Pioneering Innovator in Pharmaceutical Patents

Introduction

Kenneth Albert Brameld is a prominent inventor located in Menlo Park, California, known for his significant contributions to the pharmaceutical industry. With a remarkable portfolio of 25 patents, he has been at the forefront of innovation, particularly in the field of drug development aimed at treating various diseases.

Latest Patents

Among his latest patents, Brameld has introduced groundbreaking work in the realm of Quinolone derivatives. These compounds serve as fibroblast growth factor receptor inhibitors, which are essential for treating diseases that can be managed through the inhibition of fibroblast growth factors. His advancements also include the development of immunoproteasome inhibitors, providing compounds that inhibit specific proteasomes, which can be crucial for therapeutic strategies against ailments treatable by immunoproteasome inhibition. Additionally, his patents encompass pharmaceutical compositions containing these compounds, alongside innovative processes for their preparation.

Career Highlights

Brameld has garnered notable experience through his work with leading companies in the biotech sector. He has made significant contributions at Principia Biopharma Inc. and Roivant Sciences GmbH, where his expertise in pharmaceutical innovation helped shape the direction of drug development. His innovative mindset has fostered advancements that are not only relevant but essential for the efficacy of treatments in modern medicine.

Collaborations

Throughout his career, Kenneth has collaborated with esteemed colleagues such as Eric Brian Sjogren and David Michael Goldstein. These collaborations, characterized by a shared commitment to innovation and scientific advancement, have further solidified his reputation within the industry.

Conclusion

Kenneth Albert Brameld stands out as a visionary in pharmaceutical innovation, with an impressive array of patents emphasizing the importance of targeted treatments for various diseases. His work continues to inspire new avenues of research and development, demonstrating the profound impact that dedicated inventors can have on healthcare and therapeutic advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…